Edition:
United Kingdom

Zynerba Pharmaceuticals Inc (ZYNE.OQ)

ZYNE.OQ on NASDAQ Stock Exchange Global Market

10.93USD
20 Feb 2018
Change (% chg)

-- (--)
Prev Close
$10.93
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
107,110
52-wk High
$25.95
52-wk Low
$5.42

Select another date:

BRIEF-Zynerba Pharmaceuticals reports Q3 loss per share of $0.63

* Zynerba Pharmaceuticals reports third quarter 2017 financial results and operational highlights

Zynerba's stock on a high as cannabis-based drug succeeds in trial

Zynerba Pharmaceuticals Inc said on Thursday its cannabis-derived gel to treat genetic disorder Fragile X syndrome succeeded in significantly reducing symptoms such as anxiety in a mid-stage study.

UPDATE 3-Zynerba's stock on a high as cannabis-based drug succeeds in trial

* Shares rise nearly 60 percent (Adds details on company's plans, analyst comment, updates share price)

BRIEF-Zynerba Pharmaceuticals announces positive top line results in ZYN002 open label Phase 2 FAB-C study

* Zynerba Pharmaceuticals announces positive top line results in ZYN002 open label Phase 2 FAB-C study in children with Fragile X syndrome

Zynerba's cannabis-based gel succeeds in mid-stage study

Sept 28 Zynerba Pharmaceuticals Inc said on Thursday its cannabis-based gel succeeded in a mid-stage study of patients with Fragile X syndrome, a genetic disorder that causes learning disabilities.

Select another date: